Compare KD & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KD | TVTX |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United States | United States |
| Employees | 80000 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.8B |
| IPO Year | 2021 | 2013 |
| Metric | KD | TVTX |
|---|---|---|
| Price | $13.18 | $42.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 11 |
| Target Price | $31.00 | ★ $35.10 |
| AVG Volume (30 Days) | ★ 3.1M | 1.4M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 170.95 | 92.89 |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $15,057,000,000.00 | N/A |
| Revenue This Year | $3.73 | $43.88 |
| Revenue Next Year | $0.08 | $33.16 |
| P/E Ratio | $16.92 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.10 | $13.88 |
| 52 Week High | $43.74 | $42.13 |
| Indicator | KD | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.87 | 77.59 |
| Support Level | $12.07 | $32.62 |
| Resistance Level | $13.81 | N/A |
| Average True Range (ATR) | 0.54 | 1.98 |
| MACD | 0.17 | 0.99 |
| Stochastic Oscillator | 68.50 | 100.00 |
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in Australia / New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.